[RESEARCH BLOG] · 2026-08-11
Olema Pharmaceuticals (OLMA) – Pivotal Breast‑Cancer Data Delay Triggers **SELL** Signal Amid Crisis Regime
By Pierre Brunelle · Founder & Research Lead
Olema Pharmaceuticals closed at $10.43, down 12.65 % on the 2026‑08‑11 session (Tuesday, US session). The steep decline follows the company’s announcement that pivotal Phase 2/3 data for its lead breast‑cancer candidate, OP‑1250, will not be available until 2027, a timeline shift that has intensified the firm’s already fragile financial profile.
News & Catalysts
-
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 – Benzinga, 2026‑08‑11 14:27:24. The release explained that additional enrollment and a stronger statistical powering are required, pushing any regulatory filing to 2028.
-
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP‑3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration‑Resistant Prostate Cancer – GlobeNewswire, 2026‑05‑26 07:00:00. The partnership expands Olema’s pipeline beyond women’s oncology but does not offset near‑term cash‑burn.
-
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP‑3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting – GlobeNewswire, 2026‑05‑21 17:00:00. Early‑stage safety and activity signals were presented, but the path to pivotal trials remains long.
-
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript – Seeking Alpha, 2026‑06‑09 21:22:12. Executives highlighted OP‑1250 as a potential first‑in‑class estrogen‑receptor degrader and reiterated reliance on external financing through 2027.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – GlobeNewswire, 2026‑08‑04 16:30:00.
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – GlobeNewswire, 2026‑06‑02 16:30:00.
-
Olema Oncology to Participate in Upcoming Investor Conferences – GlobeNewswire, 2026‑05‑19 16:30:00.
These releases collectively shape the short‑term outlook: the data delay is the dominant negative catalyst, while the Bayer collaboration and early Phase 1 read‑outs provide modest upside narratives that are unlikely to offset the cash‑burn pressure.
Fundamentals and Valuation
| Metric | Value |
|---|---|
| Market‑cap | $911.0 M |
| P/E (TTM) | ‑4.92 |
| EV/EBITDA | ‑4.23 |
| P/B | 2.53 |
| ROE | ‑52.74 % |
| FCF Yield | ‑18.08 % |
| Debt‑to‑Equity | 0.15 |
| Interest Coverage | 999.0 (artificially high) |
| Analyst Target | $31.00 |
| Altman Z‑score | 7.23 |
| Value Score | 10.00 |
| Growth Score | 48.00 |
| Quality Score | 8.00 |
| Archetype | Balanced |
Key observations
- Negative earnings (P/E ‑4.92) and negative cash flow (FCF yield ‑18.08 %) confirm that Olema is still fully dependent on financing.
- Low leverage (D/E 0.15) and a nominal interest coverage figure are typical for cash‑burn biotech firms; the coverage ratio is not a meaningful safety metric when earnings are negative.
- Analyst consensus remains bullish (Buy) with a target price of $31.00, implying ~200 % upside, but this optimism is driven by the high Growth score (48) rather than current profitability.
- Altman Z‑score of 7.23 suggests a low probability of imminent bankruptcy, offering a modest cushion despite the cash‑burn trajectory.
Historical Financial Trajectory
| Year | EPS | FCF (USD M) | PE | ROE |
|---|---|---|---|---|
| 2020 | ‑0.58 | ‑19.9 | ‑85.44 | ‑6.54 % |
| 2021 | ‑1.79 | ‑52.3 | ‑5.20 | ‑24.98 % |
| 2022 | ‑2.62 | ‑82.4 | ‑0.94 | ‑53.04 % |
| 2023 | ‑2.14 | ‑83.7 | ‑6.57 | ‑38.07 % |
| 2024 | ‑2.20 | ‑104.5 | ‑2.65 | ‑31.66 % |
| 2025 | ‑1.87 | ‑146.7 | ‑13.39 | ‑33.95 % |
The EPS line has remained negative throughout, deepening in 2024 before a modest rebound in 2025. Free‑cash‑flow outflows have accelerated, reflecting rising R&D spend as the pipeline advances. The volatility in PE ratios mirrors the share‑price swings driven by clinical‑milestone news.
ETF Ownership
Olema’s institutional footprint is thin. The stock is held by a single exchange‑traded fund, CANC, which accounts for 0.48 % of the outstanding float and is ranked #48 among the fund’s holdings.
| ETF Ticker | Weight % | Rank |
|---|---|---|
| CANC | 0.48 % | #48 |
While the exposure is modest, the presence of a biotech‑focused ETF provides a small liquidity cushion and may attract additional passive capital over time.
LOPJLB Signal Read
The LOPJLB platform currently flags Olema with a SELL directional signal and assigns a Score of ‑5. The underlying market regime is classified as CRISIS, reflecting heightened volatility and risk aversion across the broader market.
- Composite performance (PERF): ‑3.90
- Quality component (FUND): 8.00
- Archetype: Balanced (Value = 10.00, Growth = 48.00, GARP = 6.00, Quality = 8.00)
The high growth score captures market expectations that OP‑1250 could become a first‑in‑class therapy, but the negative earnings, cash‑burn, and the 2027 data delay dominate the risk assessment. Readers are encouraged to explore the interactive chart on the LOPJLB site for a visual overlay of the signal components and to review the full methodology.
Full methodology details: LOPJLB methodology page
Further Reading & Resources
- Detailed stock page: https://www.lopjlb.com/stock/OLMA
- Historical earnings and transcript archive: https://www.lopjlb.com/stock/OLMA/earnings.md
- LOPJLB screener for comparable biotech opportunities: https://www.lopjlb.com/screener
The information presented herein is for research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consult professional advisors before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.